Motoneurone Disease Stroke Peripheral Neuropathy Multiple Sclerosis Lennox-Gastaut Absence Epilepsy Eye Diseases
Drug Platform Discovery Pharmacokinetics Pharmacodynamic Clinical Studies Publications
Our Mission Directors
Press Releases

Lead development, Metabolic Activity and Toxicity testingTesting compounds

  • The pre-clinical chemical mimetic development focuses on a NRP molecule deriving from a large protein called CAPS-2 involved in vesicular protein excretion.
  • The shortest amino acid chain providing all the desired bioactivities (go to background) is eleven amino acids long (NRP2945).
  • Amino acid modification (chemical mimetic generation) has been performed to enhance the overall physico-chemical stability of the molecule.
  • Currently, excellent stability over a timeframe of 1 year stored under sub-zero conditions has been achieved. CuroNZ has also achieved to create a liquid formulation (subcutaneous injection) for NRP2945. The stability of the liquid solution - injectable NRP2945 is suitable for early clinical trials.
  • Metabolic activity in blood is sufficient long for penetration of NRP2945 through the blood brain barrier to exert its mechanism of action in a hit-and-run fashion on the CNS membrane receptors. NRP2945 is quickly (within 1 hour) eliminated from the CNS which provides high safety for future paediatric clinical trials.

Toxicity Testing

A 28-day rat GLP toxicology / pharmacokinetic trial has been performed which delivered excellent safety and dose-response signals in the toxicokinetic study.

A 28-days dog GLP toxicology / pharmacokinetic study completed with emphasis on heart, lung physiology and IRWIN testing in brain tissue found no toxicity.

Click on the following aspects of the NRP drug platform to read more:

Go To:

Contact Us About Us Research Target Diseases Investors